Orphan Drugs Market 2015-2019 - Expected to Grow at a CAGR of 10.05% - Key Vendors are Celgene, Pfizer & Novartis

Dublin, March 04, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/kcb5zc/orphan_drugs) has announced the addition of the "Orphan Drugs Market 2015-2019" report to their offering.

The global orphan drugs market is expected to grow at a CAGR of 10.05% over the period 2015-2019.

An orphan drug is used to treat rare diseases or disorders. According to WHO, orphan or rare diseases are the pathological conditions that affect 0.65-1 out of 10,000 population worldwide. There are around 6,000 orphan diseases, of which 80% are genetic. Orphan drugs are developed by the pharmaceutical industry to serve the public health need. These are designated as "Orphan Designations" by the regulatory agencies to accelerate the approval process.

Biologics are expected to be a preferred treatment option for the medical fraternity, patients, and the families of patients. This in turn will raise the number of treatment-seeking patients, which results in an increase in the overall consumption of medicines.

Further, the report states that one of the challenges in conducting clinical trials in rare diseases is the smaller number of patients available for clinical studies. Enrolling enough patients in clinical studies to generate significant comparative data is therefore a major challenge.

Key vendors:

• Bristol-Mayer Squibb
• Celgene
• F. Hoffmann La Roche
• Novartis
• Pfizer
  

Key questions answered in this report:

• What will the market size be in 2019 and what will the growth rate be?
• What are the Key Market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Overview

PART 06: Pipeline snapshot

PART 07: Market landscape

PART 08: Market segmentation by product

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

PART 16: Key vendor analysis

For more information visit http://www.researchandmarkets.com/research/kcb5zc/orphan_drugs.

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Drug Discovery